Merus (NASDAQ:MRUS) Shares Bought by BIT Capital GmbH

BIT Capital GmbH increased its position in Merus (NASDAQ:MRUS) by 167.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,402 shares of the biotechnology company’s stock after acquiring an additional 13,402 shares during the period. BIT Capital GmbH’s holdings in Merus were worth $900,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Avior Wealth Management LLC purchased a new position in shares of Merus in the fourth quarter valued at $76,000. MML Investors Services LLC purchased a new position in Merus during the 3rd quarter valued at about $206,000. Gordian Capital Singapore Pte Ltd increased its holdings in Merus by 10.4% during the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company’s stock valued at $250,000 after acquiring an additional 470 shares in the last quarter. HighTower Advisors LLC raised its position in Merus by 10.9% during the fourth quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 789 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Merus in the fourth quarter valued at about $347,000. 96.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on MRUS shares. Bank of America dropped their price objective on shares of Merus from $73.00 to $70.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Piper Sandler initiated coverage on Merus in a report on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price target for the company. Citigroup increased their price objective on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Needham & Company LLC dropped their price objective on Merus from $85.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Finally, William Blair restated an “outperform” rating on shares of Merus in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $85.31.

Merus Price Performance

NASDAQ MRUS opened at $44.45 on Thursday. Merus has a 1-year low of $37.77 and a 1-year high of $61.61. The firm has a market capitalization of $3.07 billion, a P/E ratio of -11.25 and a beta of 1.15. The business’s 50-day simple moving average is $43.77 and its 200-day simple moving average is $46.13.

Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $10.57 million. On average, equities research analysts expect that Merus will post -3.85 EPS for the current fiscal year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.